High Incidence of Somatostatin Receptors in Human Meningiomas: Biochemical Characterization

Reubi, Jean–Claude; Maurer, Richard A.; Klijn, Jan G.M.; Stefanko, S. Z.; Foekens, John A.; Blaauw, G.; Blankenstein, M.A.; Lamberts, Steven W. J.

doi:10.1210/jcem-63-2-433

Cited by 172 publications

(76 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meningiomas have been shown to express somatostatin receptors both in vitro and in vivo (17,18). Somatostatin receptor scintigraphy with 111 In-octreotide was thus proposed as a tool for differentiating meningiomas from other tumors and as a method for evaluating residual disease after surgery (19).…”

Section: Discussionmentioning

confidence: 99%

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Rutten¹,

Cabay²,

Withofs³

et al. 2007

Journal of Nuclear Medicine

View full text Add to dashboard Cite

Precise delineation of the shape of skull base meningiomas is critical for their treatment and follow-up but is often difficult using conventional imaging such as CT and MRI. We report our results with PET/CT and 2-18 F-fluoro-L-tyrosine ( 18 F-TYR), a marker of amino acid transport, as part of the yearly follow-up of irradiated patients. Methods: Eleven patients (mean age, 56.5 y) with skull base meningiomas (n 5 13 lesions) previously irradiated were included. All patients received 300 MBq of 18 F-TYR and were imaged after 30 min of uptake, using a dedicated PET/CT system. The images were first visually examined, and regions of interest (ROI) were then placed over the transaxial PET slice showing the highest uptake. Another ROI was placed over the normal parietal cortex. Tumor-to-cortex activity ratios were obtained by dividing the maximum pixel value in the tumor ROI by the maximum pixel value in the cortex ROI. The PET/CT images were compared with the MR images obtained as part of routine followup. Results: Accumulation of the tracer was higher in all meningiomas than in the surrounding tissue. The tumor-to-cortex activity ratio was 2.53 6 0.35 (range, 1.3-6). Nonneoplastic tissue such as hyperemic cavernous sinus did not take up the radionuclide and was therefore easily distinguished from the meningioma. The 18 F-TYR anomalies completely overlapped with the MR image in 54% of the tumors, extended beyond the MRI lesion in 38% of the tumors, and were smaller in 8% of the tumors. Conclusion: Meningiomas of the skull base are clearly visualized using 18 F-TYR PET/CT, even after irradiation. In addition to MRI, 18 F-TYR PET/CT images may contribute to the evaluation, delineation, and follow-up of these tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Rutten¹,

Cabay²,

Withofs³

et al. 2007

Journal of Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…In human meningiomas, the expression of sstrs has been largely explored through different techniques such as in vitro autoradiography, immunohistochemistry and RT-PCR (14,(16)(17)(18)29).…”

Section: Discussionmentioning

confidence: 99%

Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density?

Barresi¹

1994

Oncol Rep

View full text Add to dashboard Cite

Abstract. Somatostatin anti-proliferative and anti-angiogenic activities, together with the expression of somatostatin receptors (sstrs), account for the use of somatostatin analogues in the treatment of human tumours. In the present study, sstr2A immunohistochemical expression was analyzed in grade II and III meningiomas and was compared with that revealed in grade I meningiomas. Thirty-five formalin-fixed paraffinembedded meningiomas, comprising 13 grade I, 19 grade II and 3 grade III tumours, according to the WHO 2007 classification, were submitted to immunohistochemical assays for sstr2A. Moreover, in the same cohort of tumours, the immunoexpression of CD105, a specific marker for neoangiogenesis, as well as the Ki-67 labelling index (LI), reflecting the proliferative activity of the meningiomas, were recorded. Sstr2A immunoreaction was evidenced in 26/35 cases and was localized at the cytoplasm and the plasma membrane in 12 and in 14 cases, respectively. Specifically, a positive staining was found in 7/13 grade I, in 16/19 grade II and in 3/3 grade III tumours, thus demonstrating that sstr2A is frequently expressed in high grade meningiomas. A significantly higher microvessel density (MVD), assessed by CD105 immunostaining and Ki-67 LI were evidenced in high grade meningiomas. A significant correlation was recorded between sstr2A expression and a high MVD of the meningiomas. The existence of a correlation between sstr2A expression and the entity of neo-angiogenesis provides the basis for the use of somatostatin analogue-based therapies in the treatment of meningiomas.

show abstract

“…Importantly, meningioma cells express members of the somatostatin receptor family (2), which provided rationale for somatostatin receptor-targeted radiopeptide therapy with radiolabeled DOTATOC in patients with progressive meningiomas. Radiolabeled DOTATOC is injected intravenously, binds to the somatostatin receptor on the target cell, and irradiates the tumor via b 2 emission.…”

mentioning

confidence: 99%

Somatostatin Receptor–Targeted Radiopeptide Therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

et al. 2015

View full text Add to dashboard Cite

Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients. Methods: Patients with progressive unresectable meningioma were treated with 90 Y-DOTATOC and 177 Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival. Results: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35; n 5 34; P 5 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004-0.63; n 5 34; P 5 0.019) were associated with longer survival. Conclusion: 90 Y-DOTATOC and 177 Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.

show abstract

High Incidence of Somatostatin Receptors in Human Meningiomas: Biochemical Characterization

Cited by 172 publications

References 20 publications

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density?

Somatostatin Receptor–Targeted Radiopeptide Therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

Contact Info

Product

Resources

About

High Incidence of Somatostatin Receptors in Human Meningiomas: Biochemical Characterization

Cited by 172 publications

References 20 publications

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

PET/CT of Skull Base Meningiomas Using 2-18F-Fluoro-L-Tyrosine: Initial Report

Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density?

Somatostatin Receptor–Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

Contact Info

Product

Resources

About

Somatostatin Receptor–Targeted Radiopeptide Therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial